Management of impulse control disorders in Parkinson's disease: Controversies and future approaches

Movement Disorders

Volumn 30, Issue 2, 2015, Pages 150-159

  Samuel, Michael ^a   Rodriguez Oroz, Maria ^b,c,d   Antonini, Angelo ^e   Brotchie, Jonathan M ^f   Ray Chaudhuri, Kallol ^a,g   Brown, Richard G ^g   Galpern, Wendy R ^h   Nirenberg, Melissa J ⁱ   Okun, Michael S ^j   Lang, Anthony E ^k  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HOSPITAL DONOSTIA   (Spain)

^c BASQUE FOUNDATION FOR SCIENCE   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e IRCCS Fondazione Ospedale San Camillo   (Italy)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF FLORIDA HEALTH   (United States)

^k TORONTO WESTERN HOSPITAL   (Canada)

more..

Author keywords

Clinical Trials; Deep Brain Stimulation; Dopamine Agonist Withdrawal; Impulse control; Management; Parkinson's

Indexed keywords

ANTIPARKINSON AGENT; APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROTIGOTINE;

BRAIN DEPTH STIMULATION; COGNITIVE THERAPY; CONTINUOUS INFUSION; DOPAMINE AGONIST WITHDRAWAL SYNDROME; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; HUMAN; IMPULSE CONTROL DISORDER; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WITHDRAWAL SYNDROME;

EID: 84964239623     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26099     Document Type: Review

References (95)

1. Napier TC, Corvol J, Grace AA, et al. Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Mov Disord 2014. In press.
2. Jahanshahi M, Obeso I, Baunez C, et al. Parkinson's disease, the subthalamic nucleus, inhibition and impulsivity. Mov Disord 2014. In press.
3. Weintraub D, David A, Evans A, et al. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord 2014. In press.
4. Evans AH, Strafella AP, Weintraub D, et al. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009;24:1561-1570.
5. Lyons KE, Friedman JH, Hermanowicz N, et al. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol 2010;33:5-10.
6. Macphee GJ, Chaudhuri KR, David AS, et al. Managing impulse control behaviours in Parkinson's disease: practical guidelines. Br J Hosp Med (Lond) 2013;74:160-166.
7. Riley DE. Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. Clin Neuropharmacol 2002;25:234-237.
8. Vitale C, Santangelo G, Erro R, et al. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases. Parkinsonism Relat Disord 2013;19:483-484.
9. Thomas A, Bonanni L, Gambi F, et al. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010;68:400-404.
10. Walsh RA, Lang AE. Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine. Mov Disord 2012;27:326.
11. Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 2010;68:963-968.
12. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-595.
13. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-445.
14. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-559.
15. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006;21:2078-2081.
16. Klos KJ, Bower JH, Josephs KA, et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005;11:381-386.
17. Seedat S, Kesler S, Niehaus DJ, et al. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000;11:185-186.
18. McElroy SL, Nelson EB, Welge JA, et al. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry 2008;69:433-440.
19. Smith N, Kitchenham N, Bowden-Jones H. Pathological gambling and the treatment of psychosis with aripiprazole: case reports. Br J Psychiatry 2011;199:158-159.
20. Rotondo A, Bosco D, Plastino M, et al. Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord 2010;25:1994-1995.
21. Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol 2007;27:107-108.
22. Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics 2014;11:78-91.
23. Papay K, Xie SX, Stern M, et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 2014;83:826-833.
24. Bastiaens J, Dorfman BJ, Christos PJ, et al. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord 2013;28:327-333.
25. Cunnington AL, White L, Hood K. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease. Parkinsonism Relat Disord 2012;18:1051-1052.
26. Pondal M, Marras C, Miyasaki J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry 2013;84:130-135.
27. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58-63.
28. O'Sullivan SS, Wu K, Politis M, et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011;134:969-978.
29. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009;132:1376-1385.
30. Voon V, Pessiglione M, Brezing C, et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 2010;65:135-142.
31. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 2014;85:840-844.
32. Rizos A, Martinez-Martin P, Martin A, et al. European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD. Mov Disord 2012;27(suppl 1):S50.
33. Schreglmann SR, Gantenbein AR, Eisele G, et al. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord 2012;18:207-209.
34. Garcia-Ruiz PJ, Sesar IA, Ares PB, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-1136.
35. Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord 2014. In press.
36. Magennis B, Cashell A, O'Brien D, Lynch T. An audit of apomorphine in the management of complex idiopathic Parkinson's disease in Ireland. 16th International Congress of Parkinson's Disease and Movement Disorders. Mov Disord 2012;27(Suppl 1):S44.
37. Todorova A, Martin A, Okai D, et al. Assessment of impulse control disorders in Parkinson's patients with infusion therapies: a single center experience. Mov Disord 2013;28(Suppl 1):S133.
38. Todorova A, Martinez-Martin P, Rizos A, et al. Daytime apomorphine infusion combined with transdermal Rotigotine patch therapy is tolerated at 2 years: a 24 hours treatment option in Parkinson's disease. Basal Ganglia 2013;127-130.
39. Antonini A. Continuous dopaminergic stimulation: from theory to clinical practice. Parkinsonism Relat Disord 2007;13(Suppl):S24-S28.
40. Catalan MJ, de Pablo-Fernandez E, Villanueva C, et al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease. Mov Disord 2013;28:2007-2010.
41. Gerschlager W, Bloem BR. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions. Mov Disord 2009;24:1858-1860.
42. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141-149.
43. Cowlishaw S, Merkouris S, Dowling N et al. Psychological therapies for pathological and problem gambling. Cochrane Database Syst Rev 2012; 11:CD008937.
44. Jimenez-Murcia S, Bove FI, Israel M, et al. Cognitive-behavioral therapy for pathological gambling in Parkinson's disease: a pilot controlled study. Eur Addict Res 2012;18:265-274.
45. Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 2013;80:792-799.
46. Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry 2011;168:1066-1074.
47. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
48. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013;368:610-622.
49. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73.
50. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9:581-591.
51. Okun MS, Weintraub D. Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa? Mov Disord 2013;28:1915-1919.
52. Samuel M, Voon V. Beyond the holy grail of motor symptoms: deep brain stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:759-760.
53. Krack P, Kumar R, Ardouin C, et al. Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord 2001;16:867-875.
54. Kulisevsky J, Berthier ML, Gironell A, et al. Mania following deep brain stimulation for Parkinson's disease. Neurology 2002;59:1421-1424.
55. Mandat TS, Hurwitz T, Honey CR. Hypomania as an adverse effect of subthalamic nucleus stimulation: report of two cases. Acta Neurochir (Wien) 2006;148:895-897.
56. Raucher-Chene D, Charrel CL, de Maindreville AD, et al. Manic episode with psychotic symptoms in a patient with Parkinson's disease treated by subthalamic nucleus stimulation: improvement on switching the target. J Neurol Sci 2008;273:116-117.
57. Bandini F, Primavera A, Pizzorno M, et al. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord 2007;13:369-371.
58. Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord 2002;17:1371-1374.
59. Sensi M, Eleopra R, Cavallo MA, et al. Explosive-aggressive behavior related to bilateral subthalamic stimulation. Parkinsonism Relat Disord 2004;10:247-251.
60. Smeding HM, Goudriaan AE, Foncke EM, et al. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007;78:517-519.
61. Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002;72:701-707.
62. Lim SY, O'Sullivan SS, Kotschet K, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009;16:1148-1152.
63. Mallet L, Schupbach M, N'Diaye K, et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci U S A 2007;104:10661-10666.
64. Rodriguez-Oroz MC, Lopez-Azcarate J, Garcia-Garcia D, et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain 2011;134:36-49.
65. Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006;21:1941-1946.
66. Halbig TD, Tse W, Frisina PG, et al. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neurol 2009;16:493-497.
67. Knobel D, Aybek S, Pollo C, et al. Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): a case report. Cogn Behav Neurol 2008;21:187-189.
68. Lhommee E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012;135:1463-1477.
69. Moum SJ, Price CC, Limotai N, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One 2012;7:e29768.
70. Shotbolt P, Moriarty J, Costello A, et al. Relationships between deep brain stimulation and impulse control disorders in Parkinson's disease, with a literature review. Parkinsonism Relat Disord 2012;18:10-16.
71. Witjas T, Baunez C, Henry JM, et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005;20:1052-1055.
72. Zahodne LB, Susatia F, Bowers D, et al. Binge eating in Parkinson's disease: prevalence, correlates and the contribution of deep brain stimulation. J Neuropsychiatry Clin Neurosci 2011;23:56-62.
73. Eusebio A, Witjas T, Cohen J, et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84:868-874.
74. Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010;133:1111-1127.
75. Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 2013;30:587-592.
76. Calabresi P, Castrioto A, Di FM, et al. New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. Lancet Neurol 2013;12:811-821.
77. Antonelli F, Ko JH, Miyasaki J, et al. Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions. Hum Brain Mapp 2014;35:2499-2506.
78. Lisman JE, Grace AA. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 2005;46:703-713.
79. Ray NJ, Miyasaki JM, Zurowski M, et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis 2012;48:519-525.
80. Voon V, Rizos A, Chakravartty R, et al. Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. J Neurol Neurosurg Psychiatry 2014;85:148-152.
81. Vriend C, Pattij T, van der Werf YD, et al. Depression and impulse control disorders in Parkinson's disease: two sides of the same coin? Neurosci Biobehav Rev 2014;38:60-71.
82. Fattore L, Spano M, Melis V, et al. Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats. Br J Pharmacol 2011;163:1550-1562.
83. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998;95:9608-9613.
84. Mitchell JM, O'Neil JP, Jagust WJ, et al. Catechol-O-methyltransferase genotype modulates opioid release in decision circuitry. Clin Transl Sci 2013;6:400-403.
85. Scott D, Taylor JR. Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task. Behav Brain Res 2014;259:164-173.
86. Albrecht B, Brandeis D, von Sandersleben HU, et al. Genetics of preparation and response control in ADHD: the role of DRD4 and DAT1. J Child Psychol Psychiatry 2014;55:914-923.
87. Bari A, Dalley JW, Robbins TW. The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats. Nat Protoc 2008;3:759-767.
88. Visanji NP, Fox SH, Johnston TH, et al. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaques. J Pharmacol Exp Ther 2009;328:276-283.
89. Millan MJ, Buccafusco JJ, Loiseau F, et al. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol 2010;13:1035-1051.
90. Koprich JB, Fox SH, Johnston TH, et al. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease. Mov Disord 2011;26:1225-1233.
91. Bosco D, Plastino M, Colica C, et al. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease. Clin Neuropharmacol 2012;35:118-120.
92. Johnston TH, Huot P, Fox SH, et al. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3, 4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease. J Pharmacol Exp Ther 2011;336:423-430.
93. Johnston TH, Fox SH, McIldowie MJ, et al. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1, 3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 2010;333:865-873.
94. Huot P, Johnston TH, Koprich JB, et al. L-745, 870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 2012;342:576-585.
95. Jentsch JD, Taylor JR, Redmond DE, Jr., et al. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology (Berl) 1999;142:78-84.